Regulation of Tumor Oxygenation by BACH1 in Breast Cancer

BACH1 在乳腺癌中对肿瘤氧合的调节

基本信息

  • 批准号:
    10693966
  • 负责人:
  • 金额:
    $ 39.83万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-09-01 至 2027-08-31
  • 项目状态:
    未结题

项目摘要

Triple negative breast cancer (TNBC), the most aggressive and metastatic subtype of breast cancer, is one of the major causes of cancer death in women. TNBC also has lower survival rates for primarily local cancers. Loss of hormone receptors and the lack of HER2 overexpression in TNBC limit treatments to cytotoxic therapies such as radiation, a key clinical strategy for 10-15% of breast cancer patients. Hypoxia is a major cause of resistance to radiotherapy, chemotherapy and even immunotherapy. Thus, identifying mechanisms to suppress the hypoxia stress response and increase the sensitivity of TNBC tumors to therapy remains a top clinical priority. Upon hypoxic stress, cancer cells initiate a transcriptional program that enables them to survive and migrate from an inhospitable microenvironment. While hypoxia-inducible factors (HIFs) are generally considered the main effectors, growing evidence suggests the hypoxia cellular response is much more complex and requires coordinated signaling with other stress response factors. One promising candidate is BACH1, a transcription factor that is induced by hypoxia and represses transcription of genes involved in heme oxidation and anti-oxidant production. Based on preliminary results, we now hypothesize that BACH1 is stabilized by hypoxia and functions as a key inducer of the cellular hypoxia response in TNBC cells leading to abnormal leaky vasculature that contributes to intratumoral hypoxia and radiation resistance. Specifically, we plan to: 1. Determine whether BACH1 is regulated by oxygen and induces a transcriptional hypoxic stress response in TNBC cells; 2. Determine whether BACH1 promotes angiogenesis, leaky vasculature and hypoxia in TNBC tumors; and 3. Determine whether BACH1 depletion sensitizes TNBC tumors to radiation. We propose that targeting BACH1 represents a unique strategy for increasing tumor oxygenation to improve the efficacy of cytotoxic, standard-of-care therapies such as radiation. Normalizing vasculature to suppress leakiness should also facilitate drug delivery to tumors. Since BACH1 can be targeted by an FDA approved drug either alone or in combination with HIF inhibitors, the proposed work could lead to a clinical trial in breast cancer and other cancer patients whose treatment involves radiation therapy.
三阴性乳腺癌(TNBC)是乳腺癌的最具侵袭性和转移性的亚型,是一种 女性癌症死亡的主要原因。TNBC也有较低的生存率,主要是当地 癌的TNBC中激素受体的丧失和HER 2过表达的缺乏限制了治疗, 细胞毒性疗法,如放射治疗,是10-15%乳腺癌患者的关键临床策略。缺氧 是对放疗、化疗甚至免疫疗法产生耐药性的主要原因。因此,识别 抑制缺氧应激反应和增加TNBC肿瘤对缺氧的敏感性的机制 治疗仍然是最优先的临床治疗。在缺氧应激时,癌细胞启动转录程序, 使它们能够从一个不适宜生存的微环境中生存和迁移。而缺氧诱导因子 缺氧诱导因子(HIF)通常被认为是主要的效应因子,越来越多的证据表明缺氧细胞反应是 更复杂,并且需要与其他应激反应因子协调的信号传导。一个有希望 候选者是BACH 1,一种由缺氧诱导并抑制基因转录的转录因子 参与血红素氧化和抗氧化剂的产生。根据初步结果,我们现在假设, BACH 1通过缺氧稳定,并作为TNBC中细胞缺氧反应的关键诱导物发挥作用 导致异常渗漏的脉管系统的细胞,导致肿瘤内缺氧和放射 阻力具体而言,我们计划:1。确定BACH 1是否受氧调节并诱导 TNBC细胞中的转录缺氧应激反应; 2.确定BACH 1是否促进血管生成, TNBC肿瘤中的渗漏脉管系统和缺氧;以及3.确定BACH 1耗竭是否使TNBC敏感 肿瘤放射治疗我们认为,靶向BACH 1是增加肿瘤发生率的独特策略。 氧合以改善细胞毒性标准护理疗法如放射的功效。正火 抑制渗漏的脉管系统也应该促进药物递送到肿瘤。由于BACH 1可以靶向 通过FDA批准的药物单独或与HIF抑制剂组合,拟议的工作可能会导致 在乳腺癌和其他癌症患者中进行的临床试验,其治疗涉及放射治疗。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MARSHA R ROSNER其他文献

MARSHA R ROSNER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MARSHA R ROSNER', 18)}}的其他基金

Regulation of RKIP Function
RKIP功能监管
  • 批准号:
    9218899
  • 财政年份:
    2017
  • 资助金额:
    $ 39.83万
  • 项目类别:
Regulation of RKIP Function
RKIP功能监管
  • 批准号:
    9567983
  • 财政年份:
    2017
  • 资助金额:
    $ 39.83万
  • 项目类别:
Tumor-stromal interactions as targets of tumor metastasis suppressors
肿瘤-基质相互作用作为肿瘤转移抑制因子的靶点
  • 批准号:
    8817963
  • 财政年份:
    2015
  • 资助金额:
    $ 39.83万
  • 项目类别:
Tumor-stromal interactions as targets of tumor metastasis suppressors
肿瘤-基质相互作用作为肿瘤转移抑制因子的靶点
  • 批准号:
    9223680
  • 财政年份:
    2015
  • 资助金额:
    $ 39.83万
  • 项目类别:
Modulation of Head and Neck Cancer by Protein Kinase C
蛋白激酶 C 对头颈癌的调节
  • 批准号:
    7104272
  • 财政年份:
    2004
  • 资助金额:
    $ 39.83万
  • 项目类别:
Modulation of Head and Neck Cancer by Protein Kinase C
蛋白激酶 C 对头颈癌的调节
  • 批准号:
    7232269
  • 财政年份:
    2004
  • 资助金额:
    $ 39.83万
  • 项目类别:
Role of Raf Kinase Inhibitory Protein in Prostate Cancer
Raf 激酶抑制蛋白在前列腺癌中的作用
  • 批准号:
    6990554
  • 财政年份:
    2004
  • 资助金额:
    $ 39.83万
  • 项目类别:
Role of Raf Kinase Inhibitory Protein in Prostate Cancer
Raf 激酶抑制蛋白在前列腺癌中的作用
  • 批准号:
    7154753
  • 财政年份:
    2004
  • 资助金额:
    $ 39.83万
  • 项目类别:
Role of Raf Kinase Inhibitory Protein in Prostate Cancer
Raf 激酶抑制蛋白在前列腺癌中的作用
  • 批准号:
    7533439
  • 财政年份:
    2004
  • 资助金额:
    $ 39.83万
  • 项目类别:
Role of Raf Kinase Inhibitory Protein in Prostate Cancer
Raf 激酶抑制蛋白在前列腺癌中的作用
  • 批准号:
    7322528
  • 财政年份:
    2004
  • 资助金额:
    $ 39.83万
  • 项目类别:

相似海外基金

Enhancing gamete cryoprotective properties of graphene oxide by dual functionalization with antioxidants and non-penetrating cryoprotectant molecules
通过抗氧化剂和非渗透性冷冻保护剂分子的双重功能化增强氧化石墨烯的配子冷冻保护特性
  • 批准号:
    24K18002
  • 财政年份:
    2024
  • 资助金额:
    $ 39.83万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
SBIR Phase I: Sustainable antioxidants for industrial process fluids
SBIR 第一阶段:工业过程流体的可持续抗氧化剂
  • 批准号:
    2222215
  • 财政年份:
    2023
  • 资助金额:
    $ 39.83万
  • 项目类别:
    Standard Grant
Development of a new bone augmentation method that enables long-term survival and long-term functional expression of transplanted cells by antioxidants
开发一种新的骨增强方法,通过抗氧化剂使移植细胞能够长期存活和长期功能表达
  • 批准号:
    23K09272
  • 财政年份:
    2023
  • 资助金额:
    $ 39.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Non-Invasive Probing Cellular Oxidative Stress and Antioxidants Therapeutic Effectiveness
非侵入性探测细胞氧化应激和抗氧化剂的治疗效果
  • 批准号:
    10652764
  • 财政年份:
    2023
  • 资助金额:
    $ 39.83万
  • 项目类别:
Mitochondria-targeting Novel Cationic Hydrazone Antioxidants for the Treatment of Preeclampsia
线粒体靶向新型阳离子腙抗氧化剂用于治疗先兆子痫
  • 批准号:
    10730652
  • 财政年份:
    2023
  • 资助金额:
    $ 39.83万
  • 项目类别:
Latent Antioxidants for Environmentally Responsible Polymer Formulations
用于环保聚合物配方的潜在抗氧化剂
  • 批准号:
    RGPIN-2018-04107
  • 财政年份:
    2022
  • 资助金额:
    $ 39.83万
  • 项目类别:
    Discovery Grants Program - Individual
Contribution of antioxidants to regeneration of rotator cuff insertion
抗氧化剂对肩袖插入再生的贡献
  • 批准号:
    22K16720
  • 财政年份:
    2022
  • 资助金额:
    $ 39.83万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of different doses of antioxidants(Vitamin E) intake on exercise induced oxidative stress, antioxidative capacity and chronic inflammation
不同剂量抗氧化剂(维生素E)摄入对运动引起的氧化应激、抗氧化能力和慢性炎症的影响
  • 批准号:
    22K11609
  • 财政年份:
    2022
  • 资助金额:
    $ 39.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Polyunsaturated fatty acid (PUFA), inflammation and antioxidants
多不饱和脂肪酸 (PUFA)、炎症和抗氧化剂
  • 批准号:
    RGPIN-2019-05674
  • 财政年份:
    2022
  • 资助金额:
    $ 39.83万
  • 项目类别:
    Discovery Grants Program - Individual
Suppressed methemoglobin formation of artificial red cell by liposomal antioxidants and its mechanism.
脂质体抗氧化剂抑制人工红细胞高铁血红蛋白形成及其机制
  • 批准号:
    22K12824
  • 财政年份:
    2022
  • 资助金额:
    $ 39.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了